Patients from the Corrona registry, an independent, observational US registry housing data on patients with rheumatic diseases, were included in Dr Harrold and colleagues’ study if they had received a PsA diagnosis; had initiated therapy with a TNFi (ie, adalimumab, etanercept, golimumab, or infliximab) between October 1, 2002, and March 21, 2013; and were aged ≥18 years.
Bimekizumab, an IL-17A and IL-17F Inhibitor, Produces High Responses in Skin and Joints in Patients with Psoriatic Arthritis
London, United Kingdom—An early-phase study of bimekizumab, a monoclonal antibody potently and selectively inhibiting interleukin (IL)-17A and IL-17F, demonstrated strong responses in skin and joints of patients with psoriatic arthritis. IL-17A and IL-17F, key proinflammatory cytokines, are overexpressed in psoriatic skin lesions, said Sophie Glatt, MD, UCB Celltech, Slough, United Kingdom, in an oral presentation at the 2016 European League Against Rheumatism Annual Congress.
London, United Kingdom—Ixekizumab (Taltz) achieved clinically significant improvement in the signs and symptoms of psoriatic arthritis (PsA), including arthritis, dactylitis, and enthesitis, as well as skin improvements, during a 28-week extension phase of a 24-week, double-blind, phase 3 trial called SPIRIT-P1 (totaling 52 weeks).
Researchers in a phase 2b study of clazakizumab suggest that this drug may become a new option for treatment of the musculoskeletal effects—but not necessarily skin lesions—associated with psoriatic arthritis (PsA). Treatment for patients with predominant musculoskeletal effects represents an unmet need.
Patients with psoriatic arthritis (PsA) who achieved persistent minimal disease activity (MDA) on golimumab treatment in the GO-REVEAL trial had better long-term benefits, including functional improvement, global assessment, and radiographic outcomes, than those who did not, according to a post hoc analysis of the GO-REVEAL trial.
Yet another benefit of weight loss! The loss of excessive weight aided by bariatric surgery appears to improve symptoms of psoriasis and psoriatic arthritis, according to a retrospective pilot study presented at the annual meeting of the American College of Rheumatology.
According to a network meta-analysis and cost-per-responder (CPR) analysis presented at the recent Academy of Managed Care Pharmacy annual meeting, adalimumab was the most cost-effective biologic for the treatment of psoriatic arthritis (PsA) in terms of incremental CPR for 2 clinical efficacy measurements and at 2 time points, weeks 12 and 24.
Page 1 of 4
Results 1 - 10 of 32
Results 1 - 10 of 32